Tags

Type your tag names separated by a space and hit enter

First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA.
Lancet. 2020 04 04; 395(10230):1137-1144.Lct

Abstract

BACKGROUND

Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first detected in China in December, 2019. In January, 2020, state, local, and federal public health agencies investigated the first case of COVID-19 in Illinois, USA.

METHODS

Patients with confirmed COVID-19 were defined as those with a positive SARS-CoV-2 test. Contacts were people with exposure to a patient with COVID-19 on or after the patient's symptom onset date. Contacts underwent active symptom monitoring for 14 days following their last exposure. Contacts who developed fever, cough, or shortness of breath became persons under investigation and were tested for SARS-CoV-2. A convenience sample of 32 asymptomatic health-care personnel contacts were also tested.

FINDINGS

Patient 1-a woman in her 60s-returned from China in mid-January, 2020. One week later, she was hospitalised with pneumonia and tested positive for SARS-CoV-2. Her husband (Patient 2) did not travel but had frequent close contact with his wife. He was admitted 8 days later and tested positive for SARS-CoV-2. Overall, 372 contacts of both cases were identified; 347 underwent active symptom monitoring, including 152 community contacts and 195 health-care personnel. Of monitored contacts, 43 became persons under investigation, in addition to Patient 2. These 43 persons under investigation and all 32 asymptomatic health-care personnel tested negative for SARS-CoV-2.

INTERPRETATION

Person-to-person transmission of SARS-CoV-2 occurred between two people with prolonged, unprotected exposure while Patient 1 was symptomatic. Despite active symptom monitoring and testing of symptomatic and some asymptomatic contacts, no further transmission was detected.

FUNDING

None.

Authors+Show Affiliations

Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA; Illinois Department of Public Health, Springfield, IL, USA.Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA; Chicago Department of Public Health, Chicago, IL, USA. Electronic address: oko9@cdc.gov.Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.Cook County Department of Public Health, Oak Forest, IL, USA.Cook County Department of Public Health, Oak Forest, IL, USA.Cook County Department of Public Health, Oak Forest, IL, USA.Cook County Department of Public Health, Oak Forest, IL, USA.Chicago Department of Public Health, Chicago, IL, USA.Chicago Department of Public Health, Chicago, IL, USA.Chicago Department of Public Health, Chicago, IL, USA.DuPage County Health Department, Wheaton, IL, USA.Chicago Department of Public Health, Chicago, IL, USA.Metro Infectious Disease Consultants, Burr Ridge, IL, USA.Metro Infectious Disease Consultants, Burr Ridge, IL, USA.Premier Primary Care Physicians, Carol Stream, IL, USA.Illinois Department of Public Health, Springfield, IL, USA.Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA; Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.Cook County Health, Chicago, IL, USA; Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.Cook County Health, Chicago, IL, USA; Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.Cook County Health, Chicago, IL, USA; Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; Lake Erie College of Osteopathic Medicine, Erie, PA, USA.One Health Office, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; Boonshoft School of Medicine, Wright State University, Dayton, OH, USA.Illinois Department of Public Health, Springfield, IL, USA.Illinois Department of Public Health, Springfield, IL, USA.Illinois Department of Public Health, Springfield, IL, USA.Illinois Department of Public Health, Springfield, IL, USA.Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.Chicago Department of Public Health, Chicago, IL, USA. Electronic address: jennifer.layden@cityofchicago.org.No affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

32178768

Citation

Ghinai, Isaac, et al. "First Known Person-to-person Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the USA." Lancet (London, England), vol. 395, no. 10230, 2020, pp. 1137-1144.
Ghinai I, McPherson TD, Hunter JC, et al. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet. 2020;395(10230):1137-1144.
Ghinai, I., McPherson, T. D., Hunter, J. C., Kirking, H. L., Christiansen, D., Joshi, K., Rubin, R., Morales-Estrada, S., Black, S. R., Pacilli, M., Fricchione, M. J., Chugh, R. K., Walblay, K. A., Ahmed, N. S., Stoecker, W. C., Hasan, N. F., Burdsall, D. P., Reese, H. E., Wallace, M., ... Layden, J. E. (2020). First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet (London, England), 395(10230), 1137-1144. https://doi.org/10.1016/S0140-6736(20)30607-3
Ghinai I, et al. First Known Person-to-person Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the USA. Lancet. 2020 04 4;395(10230):1137-1144. PubMed PMID: 32178768.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. AU - Ghinai,Isaac, AU - McPherson,Tristan D, AU - Hunter,Jennifer C, AU - Kirking,Hannah L, AU - Christiansen,Demian, AU - Joshi,Kiran, AU - Rubin,Rachel, AU - Morales-Estrada,Shirley, AU - Black,Stephanie R, AU - Pacilli,Massimo, AU - Fricchione,Marielle J, AU - Chugh,Rashmi K, AU - Walblay,Kelly A, AU - Ahmed,N Seema, AU - Stoecker,William C, AU - Hasan,Nausheen F, AU - Burdsall,Deborah P, AU - Reese,Heather E, AU - Wallace,Megan, AU - Wang,Chen, AU - Moeller,Darcie, AU - Korpics,Jacqueline, AU - Novosad,Shannon A, AU - Benowitz,Isaac, AU - Jacobs,Max W, AU - Dasari,Vishal S, AU - Patel,Megan T, AU - Kauerauf,Judy, AU - Charles,E Matt, AU - Ezike,Ngozi O, AU - Chu,Victoria, AU - Midgley,Claire M, AU - Rolfes,Melissa A, AU - Gerber,Susan I, AU - Lu,Xiaoyan, AU - Lindstrom,Stephen, AU - Verani,Jennifer R, AU - Layden,Jennifer E, AU - ,, Y1 - 2020/03/13/ PY - 2020/03/02/received PY - 2020/03/06/revised PY - 2020/03/06/accepted PY - 2020/3/18/pubmed PY - 2020/4/10/medline PY - 2020/3/18/entrez SP - 1137 EP - 1144 JF - Lancet (London, England) JO - Lancet VL - 395 IS - 10230 N2 - BACKGROUND: Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first detected in China in December, 2019. In January, 2020, state, local, and federal public health agencies investigated the first case of COVID-19 in Illinois, USA. METHODS: Patients with confirmed COVID-19 were defined as those with a positive SARS-CoV-2 test. Contacts were people with exposure to a patient with COVID-19 on or after the patient's symptom onset date. Contacts underwent active symptom monitoring for 14 days following their last exposure. Contacts who developed fever, cough, or shortness of breath became persons under investigation and were tested for SARS-CoV-2. A convenience sample of 32 asymptomatic health-care personnel contacts were also tested. FINDINGS: Patient 1-a woman in her 60s-returned from China in mid-January, 2020. One week later, she was hospitalised with pneumonia and tested positive for SARS-CoV-2. Her husband (Patient 2) did not travel but had frequent close contact with his wife. He was admitted 8 days later and tested positive for SARS-CoV-2. Overall, 372 contacts of both cases were identified; 347 underwent active symptom monitoring, including 152 community contacts and 195 health-care personnel. Of monitored contacts, 43 became persons under investigation, in addition to Patient 2. These 43 persons under investigation and all 32 asymptomatic health-care personnel tested negative for SARS-CoV-2. INTERPRETATION: Person-to-person transmission of SARS-CoV-2 occurred between two people with prolonged, unprotected exposure while Patient 1 was symptomatic. Despite active symptom monitoring and testing of symptomatic and some asymptomatic contacts, no further transmission was detected. FUNDING: None. SN - 1474-547X UR - https://www.unboundmedicine.com/medline/citation/32178768/First_known_person_to_person_transmission_of_severe_acute_respiratory_syndrome_coronavirus_2__SARS_CoV_2__in_the_USA_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(20)30607-3 DB - PRIME DP - Unbound Medicine ER -